Skip to main content

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
Cancel
×
×
Home
  • Home
Chapter
  • Get access
    Buy the print book
    Check if you have access via personal or institutional login
    Log in Register Recommend to librarian
  • Cited by 1
  • Cited by
    Crossref Citations
    Crossref logo
    This (lowercase (translateProductType product.productType)) has been cited by the following publications. This list is generated based on data provided by CrossRef.
    Perera, Vidya Bies, Robert R. Mo, Gary Dolton, Michael J. Carr, Vaughan J. McLachlan, Andrew J. Day, Richard O. Polasek, Thomas M. and Forrest, Alan 2014. Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice. British Journal of Clinical Pharmacology, Vol. 78, Issue. 4, p. 800.
    ×
  • Print publication year: 2010
  • Online publication date: May 2010

Chapter 15 - Population pharmacokinetics of antipsychotics

Export citation
Summary
Research has shown that up to 83% of friends and family members of people diagnosed with schizophrenia experience financial, emotional, and practical burdens. In their pioneering study of family psychoeducation, Falloon and colleagues found that reductions in family burden associated with family psychoeducation were associated with improvements in patient clinical status and reductions in relapse over time. The design of Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) permits investigation of the impact of random assignment to the first-generation antipsychotic perphenazine and four second-generation drugs on family outcomes over an 18-month study period. In addition, family members frequently take an active role in helping patients manage their medication and in other aspects of preventing relapse and promoting recovery. The findings of the CATIE study underscore the importance of involving family caregivers in treatment planning for their relatives with schizophrenia.

Keywords:

Recommend this book

Email your librarian or administrator to recommend adding this book to your organisation's collection.

Antipsychotic Trials in Schizophrenia
  • Online ISBN: 9780511712265
  • Book DOI: https://doi.org/10.1017/CBO9780511712265
Please enter your name
Please enter a valid email address
Who would you like to send this to *

CAPTCHA *

Skip to the audio challenge
×

References

1. LiebermanJA, StroupTS, McEvoyJP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209–23.
2. SchneiderLS, TariotPN, DagermanKS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. New England Journal of Medicine 2006;355:1525–38.
3. BigosKL, BiesRR and PollockBG. Population pharmacokinetics in geriatric psychiatry. American Journal of Geriatric Psychiatry 2006;14:993–1003.
4. AravagiriM and MarderSR. Determination of olanzapine in plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to plasma level monitoring in schizophrenic patients. AAPS PharmSci 2002;4:Abstract W5016.
5. AravagiriM, MarderSR and PollockBG. Determination of ziprasidone in human plasma by liquid chromatography-electrospray tandem mass spectrometry and its application to plasma level determination in schizophrenia patients. Journal of Chromatography. B. Analytical Technologies in the Biomedical and Life Sciences 2007;847:237–44.
6. SheinerLB, RosenbergB and MaratheVV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. Journal of Pharmacokinetics and Biopharmaceutics 1977;5:445–79.
7. BealSL and SheinerLB, eds. NONMEM Users Guides. Hanover, MD: GloboMax, LLC; 1989–98.
8. BigosKL, PollockBG, ColeyKC, et al. Sex, race, and smoking impact olanzapine exposure. Journal of Clinical Pharmacology. 2008;48:157–65.
9. CallaghanJT, BergstromRF, PtakLR and BeasleyCM.Olanzapine: Pharmacokinetic and pharmacodynamic profile. Clinical Pharmacokinetics 1999;37:177–93.
10. CarrilloJA, HerráizAG, RamosSI, GervasiniG, VizcaínoS and BenítezJ. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. Journal of Clinical Psychopharmacology 2003;23:119–27.
11. BozikasaVP, PapakostabM, NiopasbI, KaravatosaA and Mirtsou-FidanicV. Smoking impact on CYP1A2 activity in a group of patients with schizophreniaEuropean Neuropsychopharmacology 2004;14:39–44.
12. RingBJ, CatlowJ, LindsayTJ, et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapineJournal of Pharmacology & Experimental Therapeutics 1996;276:658–66.
13. BiesRR, BigosKL and PollockBG. Gender differences in the pharmacokinetics and pharmacodynamics of antidepressants. The Journal of Gender-Specific Medicine 2003;6:12–20.
14. BiesRR, BigosKL and PollockBG. Gender and Antidepressants. Vol 2. New York: Elsevier Academic Press; 2004.
15. Gex-FabryM, Balant-GorgiaAE and BalantLP.Therapeutic drug monitoring of olanzapine: The combined effect of age, gender, smoking, and comedication. Therapeutic Drug Monitoring 2003;25:46–53.
16. KellyDL, ConleyRR and TammingaCA. Differential olanzapine plasma concentrations by sex in a fixed-dose study. Schizophrenia Research 1999;40:101–4.
17. KellyDL, RichardsonCM, YuY and ConleyRR. Plasma concentrations of high-dose olanzapine in a double-blind crossover study. Human Psychopharmacology in Clinical Experience 2006;21:393–8.
18. PollockBG, WylieE, StackJA, et al. Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women. Journal of Clinical Pharmacology 1999;39:936–40.
19. KriegerN.Stormy weather: Race, gene expression, and the science of health disparities. American Journal of Public Health 2005;95:2155–60.
20. Ingelman-SundbergM, DalyAK and NebertDW, eds. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. http://www.cypalleles.ki.se/. 2006.
21. FengY, PollockBG, ReynoldsC and BiesRR. Paroxetine pharmacokinetics in geriatric patients. AAPS PharmSci 2004:Abstract M1116.
22. FengY, PollockBG, FerrellRE, KimakMA, ReynoldsCF III and BiesRR.Paroxetine: Population pharmacokinetic analysis in late-life depression using sparse concentration sampling. British Journal of Clinical Pharmacology 2006;61:558–69.
23. MurayamaN, SoyamaA, SaitoY, et al. Six novel nonsynonymous CYP1A2 gene polymorphisms: Catalytic activities of the naturally occurring variant enzymesJournal of Pharmacology & Experimental Therapeutics 2004;308:300–6.
24. FengY, PollockBG, ColeyKC, et al. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. British Journal of Clinical Pharmacology 2008;66:629–39.
25. AravagiriM, MarderSR, VanPuttenT and MidhaKK.Determination of risperidone in plasma by high-performance liquid chromatography with electrochemical detection: Application to therapeutic drug monitoring in schizophrenic patients. Journal of Pharmaceutical Sciences 1993;82:447–9.
26. AkaikeH. A new look at the statistical model identification. IEEE Transactions on Automatic Control 1974;AC-19:716–23.
27. GreenB and DuffullSB. Development of a dosing strategy for enoxaparin in obese patients. British Journal of Clinical Pharmacology 2003;56:96–103.
28. AichhornW, WeissU, MarksteinerJ, et al. Influence of age and gender on risperidone plasma concentrations. Journal of Psychopharmacology 2005;19:395–401.
29. MannensG, HuangML, MeuldermansW, HendrickxJ, WoestenborghsR and HeykantsJ. Absorption, metabolism, and excretion of risperidone in humans. Drug Metabolism and Disposition 1993;21:1134–41.
30. SnoeckE, Van PeerA, SackM, et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology (Berl) 1995;122:223–9.
31. SchneiderL, DagermanK and InselP.Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. Journal of the American Medical Association 2005;294:1934–43.
32. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. http://www.imm.ki.se/CYPalleles/.
33. KagimotoM, HeimM, KagimotoK, ZeuginT and MeyerUA.Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. The Journal of Biological Chemistry 1990;265:17209–14.
34. BradfordLD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002;3:229–43.
35. FengY, PollockBG, FerrellRE, KimakMA, ReynoldsCF, III and BiesRR.Paroxetine: Population pharmacokinetic analysis in late-life depression using sparse concentration sampling. British Journal of Clinical Pharmacology 2006;61:558–69.
36. FengY, PollockB, ReynoldsC and BiesR. Paroxetine pharmacokinetics in geriatric patients. AAPS PharmSci 2004; Abstract M1116.
37. SaitoM, Yasui-FurukoriN, NakagamiT, FurukoriH and KanekoS. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients. Journal of Clinical Psychopharmacology 2005;25:527–32.
38. SpinaE, AvenosoA, ScordoMG, et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: A clinically relevant pharmacokinetic drug interaction. Journal of Clinical Psychopharmacology 2002;22:419–23.
39. DeVaneCL and NemeroffCB.Clinical pharmacokinetics of quetiapine: An atypical antipsychotic. Clinical Pharmacokinetics 2001;40:509–22.
40. TuckerWE Jr.Preclinical toxicology of bupropion: An overview. Journal of Clinical Psychiatry 1983;44(Pt. 2):60–2.
41. HesseLM, SakaiY, VishnuvardhanD, LiAP, von MoltkeLL and GreenblattDJ.Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: Comparison with rifampicin. The Journal of Pharmacy and Pharmacology 2003;55:1229–39.
42. SchroederDH. Metabolism and kinetics of bupropion. Journal of Clinical Psychiatry 1983;44(Pt. 2):79–81.
43. KimkoHC, ReeleSS, HolfordNH and PeckCC. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clinical Pharmacology and Therapeutics 2000;68:568–77.
44. MauriMC, VolonteriLS, ColasantiA, FiorentiniA, De GaspariIF and BareggiSR.Clinical pharmacokinetics of atypical antipsychotics: A critical review of the relationship between plasma concentrations and clinical response. Clinical Pharmacokinetics 2007;46:359–88.
45. NemeroffCB, KinkeadB and GoldsteinJ.Quetiapine: Preclinical studies, pharmacokinetics, drug interactions, and dosing. Journal of Clinical Psychiatry 2002;63(Suppl. 13):5–11.
46. CheerSM and WagstaffAJ.Quetiapine. A review of its use in the management of schizophrenia. CNS Drugs 2004;18:173–99.
47. SmallJG, HirschSR, ArvanitisLA, MillerBG and LinkCG.Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Archives of General Psychiatry 1997;54:549–57.
48. HasselstromJ and LinnetK.Quetiapine serum concentrations in psychiatric patients: The influence of comedication. Therapeutic Drug Monitoring 2004;26:486–91.
49. ThyrumPT, WongYW and YehC. Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2000;24:521–33.
50. JaskiwGE, ThyrumPT, FullerMA, ArvanitisLA and YehC. Pharmacokinetics of quetiapine in elderly patients with selected psychotic disorders. Clinical Pharmacokinetics 2004;43:1025–35.
51. KimkoHC, ReeleSS, HolfordNH and PeckCC. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clinical Pharmacology and Therapeutics 2000;68:568–77.
52. Eggert HansenC, Rosted ChristensenT, ElleyJ, et al. Clinical pharmacokinetic studies of perphenazine. British Journal of Clinical Pharmacology 1976;3:915–23.
53. JerlingM, DahlML, Aberg-WistedtA, et al. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clinical Pharmacology and Therapeutics 1996;59:423–8.
54. Schering Corporation. Product Information: Trilafon(R), perphenazine. Kenilworth, NJ: Schering Corporation; 07/2002.
55. WanYJ, PolandRE, HanG, et al. Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California. Pharmacogenetics 2001;11:489–99.
56. LeathartJB, LondonSJ, StewardA, AdamsJD, IdleJR and DalyAK. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics 1998;8:529–41.
57. WennerholmA, DandaraC, SayiJ, et al. The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity. Clinical Pharmacology and Therapeutics 2002;71:77–88.
58. MasimirembwaC, PerssonI, BertilssonL, HaslerJ and Ingelman-SundbergM. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: Association with diminished debrisoquine hydroxylase activity. British Journal of Clinical Pharmacology 1996;42:713–9.
59. OlesenOV and LinnetK. Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. British Journal of Clinical Pharmacology 2000;50:563–71.
60. KroonLA. Drug interactions with smoking. American Journal of Health-System Pharmacy 2007;64:1917–21.
61. MauriMC, VolonteriLS, ColasantiA, FiorentiniA, De GaspariIF and BareggiSR.Clinical pharmacokinetics of atypical antipsychotics: A critical review of the relationship between plasma concentrations and clinical response. Clinical Pharmacokinetics 2007;46:359–88.
62. PerryPJ, LundBC, SangerT and BeasleyC.Olanzapine plasma concentrations and clinical response: Acute phase results of the North American Olanzapine Trial. Journal of Clinical Psychopharmacology 2001;21:14–20.
63. PerryPJ, SangerT and BeasleyC. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. Journal of Clinical Psychopharmacology 1997;17:472–7.
64. LaneHY, GuoSC, HwangTJ, et al. Effects of olanzapine plasma concentrations on depressive symptoms in schizophrenia: A pilot study. Journal of Clinical Psychopharmacology 2002;22:530–2.
65. FellowsL, AhmadF, CastleDJ, DusciLJ, BulsaraMK and IlettKP. Investigation of target plasma concentration-effect relationships for olanzapine in schizophrenia. Therapeutic Drug Monitoring 2003;25:682–9.
66. MauriMC, SteinhilberCPC, MarinoR, et al. Clinical outcome and olanzapine plasma levels in acute schizophrenia. European Psychiatry 2005;20:55–60.
Cancel
Confirm
×